【摘要】 目的 探讨重组人促红细胞生成素在初次行髋膝关节置换术高龄贫血患者中的应用效果。方法 选取2021年5月至2023年5月在钦州市第一人民医院初次行髋膝关节置换术的80例高龄贫血患者为观察对象，按治疗方法不同分为对照组与治疗组，各40例。对照组给予氨甲环酸治疗，治疗组在对照组基础上给予重组人促红细胞生成素治疗。比较两组的治疗效果。结果 治疗前，两组的血红蛋白（Hb）、红细胞计数（RBC）及红细胞压积（Hct）无显著差异（P>0.05）；治疗后7 d，两组的Hb、RBC及Hct均明显升高，且治疗组高于对照组，差异具有统计学意义（P<0.05）。治疗组的并发症总发生率为12.50%，略低于对照组的22.50%，但组间无显著差异（P>0.05）。治疗组的失血量少于对照组，差异具有统计学意义（P<0.05）；两组的输血率、输血量无显著差异（P>0.05）。结论 重组人促红细胞生成素联合氨甲环酸能够有效改善初次行髋膝关节置换术的高龄贫血患者的围术期失血情况，有降低术后并发症发生率的可能，值得临床进一步研究与探索。更多还原

【Abstract】 Objective To investigate the application effect of recombinant human erythropoietin in elderly anemia patients undergoing hip and knee replacement surgery for the first time. Methods From May 2021 to May 2023, 80 elderly anemia patients who underwent hip and knee replacement surgery for the first time in the First People’s Hospital of Qinzhou were selected as the observation objects. According to different treatment methods, the patients were divided into control group and treatment group, with 40 cases in each group. The control group was treated with tranexamic acid, and the treatment group was treated with recombinant human erythropoietin on the basis of the control group. The therapeutic effects of the two groups were compared. Results Before treatment, there were no significant differences in hemoglobin(Hb), red blood cell count(RBC) and hematocrit(Hct) between the two groups(P>0.05); after treatment for 7 d, the Hb, RBC and Hct in two groups were significantly increased, and those of the treatment group were higher than the control group, the differences were statistically significant(P<0.05). The total incidence of complications in the treatment group was 12.50%,which was slightly lower than 22.50% in the control group, but there was no significant difference between the two groups(P>0.05). The blood loss of the treatment group was less than that of the control group, and the difference was statistically significant(P<0.05); there were no significant differences in blood transfusion rate and blood transfusion volume between the two groups(P>0.05). Conclusion Recombinant human erythropoietin combined with tranexamic acid can effectively improve the perioperative blood loss of elderly anemia patients undergoing primary hip and knee replacement surgery, and may reduce the incidence of postoperative complications, which is worthy of further clinical research and exploration.更多还原